U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H10FN3O3S
Molecular Weight 247.2481
Optical Activity ( - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMTRICITABINE

SMILES

c1c(c(=N)nc(n1[C@]2([H])CS[C@]([H])(CO)O2)O)F

InChI

InChIKey=XQSPYNMVSIKCOC-NTSWFWBYSA-N
InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1

HIDE SMILES / InChI

Molecular Formula C8H10FN3O3S
Molecular Weight 247.2481
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including: http://www.emory.edu/news/Releases/emtri/

Emtricitabine was discovered by Emory researchers Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi and Dr. Woo-Baeg Choi and licensed to Triangle Pharmaceuticals by Emory University in 1996. Triangle was acquired by Gilead in 2003. Emtricitabine, marketed by Gilead as Emtriva, was first approved by the U.S. Food and Drug Administration in July 2003 for the treatment of HIV infection in combination with other antiretroviral agents. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination.

Originator

Curator's Comment:: Liotta, Schinazi and Choi (Emory University) and licensed to Triangle Pharmaceuticals by Emory University in 1996

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
EMTRIVA

Approved Use

EMTRIVA is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection: • EMTRIVA should not be coadministered with ATRIPLA™, TRUVADA®, or Lamivudine-containing products (see WARNINGS). • In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history (see MICROBIOLOGY).

Launch Date

1.057104E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.8 μg/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.7 μg/mL
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10 μg × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.6 μg × h/mL
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.2 h
5.6 mg/kg 1 times / day steady-state, oral
dose: 5.6 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
96%
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EMTRICITABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
dolutegravir(50 mg)
tenofovir disoproxil fumarate(300 mg)
Sources:
unhealthy, 26 - 42 years
n = 717
Health Status: unhealthy
Condition: HIV-1
Age Group: 26 - 42 years
Sex: M+F
Population Size: 717
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (grade 2-5, 8 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache grade 2-5, 8 patients
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
dolutegravir(50 mg)
tenofovir disoproxil fumarate(300 mg)
Sources:
unhealthy, 26 - 42 years
n = 717
Health Status: unhealthy
Condition: HIV-1
Age Group: 26 - 42 years
Sex: M+F
Population Size: 717
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Perspectives for the treatment of hepatitis B virus infections.
1999 Jul
Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
2000 Dec 4
Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks.
2000 Jun
Antiviral drugs: current state of the art.
2001 Aug
Antiviral L-nucleosides specific for hepatitis B virus infection.
2001 Jan
New developments in anti-HIV chemotherapy.
2001 Jan-Feb
New antiretroviral agents.
2001 Mar
Highlights in the development of new antiviral agents.
2002 Apr
Treatment of chronic hepatitis B: case selection and duration of therapy.
2002 Apr
Management of patients with chronic hepatitis B.
2002 Apr
Gateways to clinical trials.
2002 Dec
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
2002 Jul
Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.
2002 Jun
Viral pharmacodynamic model for (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) in chronically infected woodchucks.
2002 May
Gateways to clinical trials.
2002 Nov
Therapy of chronic hepatitis B: current challenges and opportunities.
2002 Nov
Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
2002 Sep
Treatment of chronic hepatitis B in 2002.
2003
US FDA approves Emtriva (FTC).
2003 Aug
The continuing evolution of HIV therapy.
2003 Dec
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
2003 Dec
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
2003 Dec 1
In vitro activity of potential anti-poxvirus agents.
2003 Jan
Gateways to clinical trials.
2003 Jan-Feb
Reproductive toxicology profile of emtricitabine in mice and rabbits.
2003 Jan-Feb
Gateways to clinical trials.
2003 Jul-Aug
Gateways to clinical trials.
2003 Jun
New antiretroviral drugs.
2003 Mar
Current and future antiviral agents for chronic hepatitis B.
2003 Mar
Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type.
2003 Mar 1
Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase.
2003 May
Once-a-day highly active antiretroviral therapy: a systematic review.
2003 May 1
Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
2003 Nov 10
Three new drugs approved by FDA.
2003 Nov-Dec
FDA notifications. NRTI Emtriva receives FDA approval.
2003 Oct
Gateways to clinical trials.
2003 Oct
Emtricitabine/tenofovir disoproxil fumarate.
2004
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.
2004
[Approval of a new nucleoside. Component of complete once daily regimen].
2004 Apr 26
Newer treatments for HIV in children.
2004 Feb
Antiviral drugs in current clinical use.
2004 Jun
Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.
2004 Jun
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
2004 Mar
Initial therapy for human immunodeficiency virus: broadening the options.
2004 Mar-Apr
New drugs of 2003.
2004 Mar-Apr
Gateways to clinical trials.
2004 May
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
2004 Oct
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
2004 Sep
New nucleoside/nucleotide backbone options: a review of recent studies.
2004 Sep 1
Intracellular pharmacology of emtricitabine and tenofovir.
2004 Sep 15
Patents

Sample Use Guides

Emtriva® (emtricitabine) dosage. Adult Patients (18 years of age and older):one 200 mg capsule administered once daily orally (Capsules). 240 mg (24 mL) administered once daily orally (Oral Solution). Pediatric Patients (0–3 months of age): 3 mg/kg administered once daily orally (Oral Solution). Pediatric Patients (3 months through 17 years): 6 mg/kg up to a maximum of 240 mg (24 mL) administered once daily orally (Oral Solution), for children weighing more than 33 kg who can swallow an intact capsule, one 200 mg capsule administered once daily orally (Capsules).
Route of Administration: Oral
emtricitabine EC50 0.99 μM (in vitro activity against HIV-2)
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:59:29 UTC 2021
Edited
by admin
on Fri Jun 25 23:59:29 UTC 2021
Record UNII
G70B4ETF4S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMTRICITABINE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
524W91
Code English
EMTRICITABINE, (-)-
Common Name English
STRIBILD COMPONENT EMTRICITABINE
Brand Name English
EMTRICITABINE COMPONENT OF STRIBILD
Brand Name English
EVIPLERA COMPONENT EMTRICITABINE
Brand Name English
DESCOVY COMPONENT EMTRICITABINE
Common Name English
5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE (2R,5S)
Common Name English
EMTRICITABINE COMPONENT OF DESCOVY
Common Name English
EMTRICITABINE COMPONENT OF TRUVADA
Brand Name English
EMTRICITABINE [USP-RS]
Common Name English
EMTRICITABINE COMPONENT OF GENVOYA
Brand Name English
DESCOVY COMPONENT OF EMTRICITABINE
Common Name English
TRUVADA COMPONENT EMTRICITABINE
Brand Name English
2(1H)-PYRIMIDINONE, 4-AMINO-5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-
Systematic Name English
EMTRIVA
Brand Name English
ATRIPLA COMPONENT EMTRICITABINE
Common Name English
(-)-EMTRICITABINE
Common Name English
FTC
Common Name English
ODEFSEY COMPONENT EMTRICITABINE
Brand Name English
EMTRICITABINE [MART.]
Common Name English
COVIRACIL
Brand Name English
EMTRICITABINE [MI]
Common Name English
EMTRICITABINE [EMA EPAR]
Common Name English
EMTRICITABINE COMPONENT OF ODEFSEY
Brand Name English
EMTRICITABINE [VANDF]
Common Name English
EMTRICITABINE [ORANGE BOOK]
Common Name English
5-FLUORO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
Systematic Name English
BIKTARVY
Brand Name English
EMTRICITABINE COMPONENT OF EVIPLERA
Brand Name English
EMTRICITABINE [JAN]
Common Name English
524-W-91
Code English
EMTRICITABINE [HSDB]
Common Name English
EMTRICITABINE [USAN]
Common Name English
FTC-(-)
Code English
EMTRICITABINUM [WHO-IP LATIN]
Common Name English
EMTRICITABINE COMPONENT OF ATRIPLA
Common Name English
EMTRICITABINE [WHO-IP]
Common Name English
EMTRICITABINE [WHO-DD]
Common Name English
(-)-FTC
Common Name English
BW-524W91
Code English
EMTRICITABINE [INN]
Common Name English
(2R-CIS)-4-AMINO-5-FLUORO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-2(1H)-PYRIMIDINONE
Systematic Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (FTC/TEN)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (EFV/FTC/TEN)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS EMTRIVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AF09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS DESCOVY (AUTHORIZED: HIV INFECTIONS )
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
FDA ORPHAN DRUG 569716
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NCI_THESAURUS C1557
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR18
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175462
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000009947
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR06
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS STRIBILD (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
LIVERTOX 346
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR08
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EMA ASSESSMENT REPORTS GENVOYA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AF09
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR06
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR03
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
FDA ORPHAN DRUG 559316
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NCI_THESAURUS C97452
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
EU-Orphan Drug EU/3/14/1420
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR19
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-VATC QJ05AR03
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR20
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR17
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
NDF-RT N0000175459
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
WHO-ATC J05AR08
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
Code System Code Type Description
HSDB
7337
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
DRUG BANK
DB00879
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
EPA CompTox
143491-57-0
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
PUBCHEM
60877
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
NCI_THESAURUS
C47509
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
EVMPD
SUB01882MIG
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
INN
7822
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
MERCK INDEX
M4892
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY Merck Index
MESH
C122114
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL885
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
FDA UNII
G70B4ETF4S
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
EMTRICITABINE
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY Description: White to almost white, crystalline powder. Solubility: Freely soluble in methanol R and water R, practically insoluble in dichloromethane R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Emtricitabine should be kept in a tightly closed container. Additional information: Emtricitabine may exhibit polymorphism.
DRUG CENTRAL
1003
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
CAS
143491-57-0
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
USP_CATALOG
1235106
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY USP-RS
LACTMED
Emtricitabine
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
WIKIPEDIA
EMTRICITABINE
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY
RXCUI
276237
Created by admin on Fri Jun 25 23:59:30 UTC 2021 , Edited by admin on Fri Jun 25 23:59:30 UTC 2021
PRIMARY RxNorm
Related Record Type Details
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
IC50
RACEMATE -> ENANTIOMER
TRANSPORTER -> INHIBITOR
ENANTIOMER -> ENANTIOMER
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
About 4% of dose
MINOR
URINE
METABOLITE -> PARENT
9% of dose
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC